IL15 and acute graft versus host disease: The 180-day cumulative incidence of grade II–IV acute GVHD was 24% in patients with day 7 IL-15 levels>median (12.5 pg/mL) versus 28% in patients with day 7 IL-15 levels ≤ median (P = 0.8) (Figure 3C).